Feed aggregator

Pfizer updates company position in Russia

World Pharma News - Mon, 03/14/2022 - 11:00
Pfizer Inc. (NYSE: PFE) Pfizer stands with the unified global community across the public, private and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created.

The international community has implemented unprecedented sanctions to Russia.

Mutations leading to omicron variant did not enable virus to fully escape immune system

World Pharma News - Fri, 03/11/2022 - 11:00
People who gained immunity - either through vaccination or exposure - against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen's omicron variant. That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response,

Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy

World Pharma News - Thu, 03/10/2022 - 13:00
Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.

Under the terms of the initial agreement, the Carisma Therapeutics manufacturing process will be transferred to the Novartis Cell Therapy Site in Morris Plains, U.S, starting in the coming days.

Stealth nanomedicines combat cancer and cut toxic effects of chemo

World Pharma News - Thu, 03/10/2022 - 11:00
Nanomedicines - typically drugs hidden within nanoscopic fatty membranes ('liposomes') - have potential to transform chemotherapy treatments, improving drug delivery and reducing toxic side effects for thousands of cancer patients every year.

Now, world first research conducted by the University of South Australia has identified that the frequently used chemotherapy drug (5-FU or Fluorouracil) is 100 per cent more effective at targeting tumours (rather than surrounding tissues) when administered using an optimised liposomal formulation.

COVID-19 beliefs influenced by politicians, not scientists, researchers suggest

World Pharma News - Wed, 03/09/2022 - 13:00
As COVID-19 upended societal norms when it swept through the United States in 2020, a second pandemic - or "infodemic" - was also on the rise. An analysis of Twitter users by researchers at the University of California, Davis, and University of Texas, Austin, suggests that Republican-identifying individuals who believe their local government has positive intentions are vulnerable to believing politically fueled COVID-19 misinformation.

Scientists identify possible new treatment for COVID-19

World Pharma News - Wed, 03/09/2022 - 11:00
Investigators at Cedars-Sinai have identified a potential new therapy for COVID-19: a biologic substance created by reengineered human skin cells.

Scientists found the substance stopped SARS-CoV-2, the virus that causes COVID-19, from reproducing itself and also protected infected cells when tested in human lung cells.

Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases

World Pharma News - Tue, 03/08/2022 - 13:00
Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets.

New strategy for COVID-19 prophylaxis

World Pharma News - Tue, 03/08/2022 - 11:00
SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. Researchers led by Prof. Dr. Gunther Hartmann from the Institute of Clinical Chemistry and Clinical Pharmacology at the University Hospital Bonn, in cooperation with other members of the cluster of excellence ImmunoSensation2 at the University of Bonn, have shown this in mice.

Statement on humanitarian aid in Ukraine

World Pharma News - Mon, 03/07/2022 - 13:00
Ugur Sahin, CEO and Co-Founder of BioNTech: "We at BioNTech are closely following the tragic situation in Ukraine and our thoughts are with everyone affected. As a company with employees from 60 countries, we know that diversity and community are stronger than pursuing single-sided interests. We join the call of the global community and urge those involved to return to peaceful coexistence in the region for the sake of all people.

AI-designed protein awakens silenced genes, one by one

World Pharma News - Mon, 03/07/2022 - 11:00
By combining CRISPR technology with a protein designed with artificial intelligence (AI), it is possible to awaken individual dormant genes by disabling the chemical “off switches” that silence them. Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports.